BeyondSpring, Inc. - Ordinary Shares (BYSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BYSI Stock Price Chart Interactive Chart >
BYSI Price/Volume Stats
|Current price||$15.36||52-week high||$33.00|
|Prev. close||$22.91||52-week low||$8.90|
|Day high||$19.70||Avg. volume||1,319,113|
|50-day MA||$19.31||Dividend yield||N/A|
|200-day MA||$13.52||Market Cap||600.67M|
BeyondSpring, Inc. - Ordinary Shares (BYSI) Company Bio
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. The co is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.
Most Popular Stories View All
BYSI Latest News Stream
|Loading, please wait...|
BYSI Latest Social Stream
View Full BYSI Social Stream
Latest BYSI News From Around the Web
Below are the latest news stories about BeyondSpring Inc that investors may wish to consider to help them evaluate BYSI as an investment opportunity.
BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Congress. Plinabulin combined with G-CSF to prevent CIN is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30. The data showed that the severe neutropenia endpoint is correlated with clinically meaningful endpoints in a meta-analysis with over 7000 patients. Relat
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021.NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of innovative cancer therapeutics, today announced new positive data on plinabulin from its chemotherapy-induced neutropenia (CIN) p
Joining us on today's call is Dr. Lan Huang, BeyondSpring's Co-Founder, Chairman and Chief Executive Officer; Dr. Ramon Mohanlal, Executive Vice President, Research and Development and Chief Medical Officer; Richard Daly, Chief Operating Officer; and Elizabeth Czerepak, Chief Financial Officer. It is now my pleasure to turn the call over to Dr. Lan Huang.
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- Management to host a call today at 8:00 am ETNEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate events. “We had a very productive first half of 2021. Importantly, we were thrilled to announce positive data from our reg
BYSI Price Returns